Eden Research plc Appointment of Non-Executive Director (0278Y)

TIDMEDEN

RNS Number : 0278Y

Eden Research plc

02 September 2022

2 September 2022

Eden Research Plc

("Eden" or "Company")

Appointment of Non-Executive Director

Eden Research plc (AIM: EDEN; OTCQB: EDNSF), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, today announces the appointment of Richard Horsman as Non-Executive Director, with effect from 1 September 2022.

Richard brings over 25 years of AIM and Main Market experience to the team, having worked in both Executive and Non-Executive roles across a broad spectrum of businesses and industries. He has experience in delivering both organic and acquisition-based growth that will support Eden in delivering on its strategic objectives. Richard also has hands on agricultural experience, having owned and operated a commercial farm, and gaining a Diploma from Plumpton Agricultural College.

Richard also holds non-executive roles at broadband, fixed line and mobile solutions business, Toople plc, and Gardien Group, a provider of software and services to the printed circuit board industry. Previous non-executive roles have included AIM-listed oil exploration and technology company Tomco plc, and specialty pharmaceutical business, Plethora Solutions plc.

Prior to his non-executive career, Richard served a 9-year tenure as CEO of Cybit Holdings plc, a leading provider of ASP based software solutions for the vehicle and asset management market. In this role, he defined the company's market strategy, recruiting a team to establish a leading product and services portfolio. Richard built Cybit to become a European market leader, with consistent double-digit revenue and profit growth, before leading its sale to Francisco Partners, in late 2009, which delivered a 106% premium to the share price.

Eden Chairman Lykele van der Broek commented: "With over 25 years' executive-level experience in both public and privately owned businesses, Richard is a valuable addition to the Eden team. As the only AIM-listed business focused on sustainable biopesticides, Eden is dedicated to growing the business to meet the rising needs of farmers across the globe, who are seeking viable alternatives to conventional chemical pesticides, as they are increasingly regulated out of the market. Richard's wealth of knowledge and experience will provide an additional perspective as we continue to focus on our growth strategy and pursue opportunities across new geographies and products lines, both organically and potentially through industry consolidation."

Regulatory Disclosures:

In accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies, Richard John Horsman, aged 61, has held the following directorships in the past five years:

 
 Current Directorships:               Directorships held in the past 
                                       five years: 
 Toople plc                           Tomco Energy plc 
 Gardien (SEA) Pte. Ltd.              Ucamco NV 
 J.C. Mackinlay and Co. Limited 
 Altar Cottages Charity 
 Crowhurst Relief in Need Charities 
 High Lees Farm Partnership

For further information, contact:

 
 Eden Research plc                             www.edenresearch.com 
  Sean Smith                                          01285 359 555 
  Alex Abrey 
 Cenkos Securities (NOMAD and broker) 
  Giles Balleny / Max Gould (Corporate 
  Finance) 
  Michael Johnson (Sales)                             020 7397 8900 
 Hawthorn Advisors                        eden@hawthornadvisors.com 
  Stephen Atkinson 
  Victoria Ainsworth

Notes to Editors:

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has two products currently on the market:

Based on plant-derived active ingredients, Mevalone (R) is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

Cedroz (TM) is a bio-nematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

Eden's Sustaine (R) encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

   For more information about Eden, please visit:   www.edenresearch.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAFFFSIAFILIIF

(END) Dow Jones Newswires

September 02, 2022 02:01 ET (06:01 GMT)

Eden Research (AQSE:EDEN.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024